Skip to Content
Search Menu

FDA Approves Lecanemab for Treatment of Early Alzheimer’s Disease

FDA has given full accelerated approval of lecanemab for treatment of early Alzheimer’s Disease.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Positive Clinical Effects in the Early Stages of Alzheimer’s Disease: A Focus on Disease-Modifying Therapies

/ BestPractice Nordic
Alzheimer'sEAN24
Anne Koivisto

The Risk of Alzheimer’s Disease Can Develop Over 10-20 Years Before the Cognitive Symptoms Appear

/ Anne Koivisto
Alzheimer'sNeurologipäivät24 Play the Video 02:35
Eino Solje

New Biomarkers Will Revolutionize Clinical Practice for Early Onset Alzheimer’s and Dementia

/ Eino Solje
Alzheimer'sNeurologipäivät24 Play the Video 1:25

Mechanistic Exploration and the Development of New Biomarkers for Alzheimer’s Disease – Focusing on the Brain ‘Garbage’ Clearance System

/ Janet Jianying Zhang / He-Ling Wang / Anne-Brita Knapskog / Geir Selbæk / Evandro Fei Fang
Alzheimer's
Kristian Steen Frederiksen

New Treatments for Early Alzheimer’s On The Way

/ Kristian Steen Frederiksen
Alzheimer'sEAN24 Play the Video 4:05
Kristian Steen Frederiksen

New Treatments for Alzheimer’s Disease with Anti-Amyloid Antibodies

/ Kristian Steen Frederiksen
Alzheimer'sEAN24 Play the Video 4:28
Michael Schöll

Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis

/ Michael Schöll
Alzheimer'sEAN24 Play the Video 3:15
Sanna-Kaisa Herukka

Anti-Amyloid Antibodies in Alzheimer’s Disease: New Treatments on the Horizon

/ Sanna-Kaisa Herukka
Alzheimer'sEAN24 Play the Video 1:34
Ludmilla Morozova-Roche

The Role of Pro-Inflammatory S100A9 Protein in Amyloid-Neuroinflammatory Cascade in Neurodegenerative Diseases

/ Ludmilla Morozova-Roche
Alzheimer'sEAN24Parkinson's Play the Video 4:38
Back to top